43 results about "Polyinosinic Acids" patented technology

The invention provides a preparation method of polyinosinic-polycytidylic acid dry powder. The method comprises the following steps: (1) respectively dissolving polyinosinic acid and polycytidysic acid in a phosphate buffer solution, mixing the solution, adding a stabilizer, uniformly mixing the stabilizer and the solution, and performing heat preservation on the mixture at the temperature of 40-100DEG C; (2) naturally cooling the reaction liquid obtained in the step (1), mixing the reaction liquid with an organic solvent, standing for precipitating, and drying the precipitate, thereby obtaining the polyinosinic-polycytidylic acid dry powder. The preparation method has the beneficial effects that the prepared polyinosinic-polycytidylic acid dry powder has a complete double-helix structural features and physiological activity, the quality and the stability are better than those of the polyinosinic-polycytidylic acid at a solution state, a stronger enzymolysis-resisting performance can be achieved compared with the bare polyinosinic-polycytidylic acid after entering a living body, so that the curative effect can be enhanced. The polyinosinic-polycytidylic acid is purified in the process for making the polyinosinic-polycytidylic acid solution into the dry powder, a plurality of small-molecular-weight substances and impurities can be removed, the toxic and side effects can be reduced, and the quality of the polyinosinic-polycytidylic acid can be improved.

The invention discloses a preparation method of a polyinosinic acid-polycytidylic acid lyophilized powder injection. The method comprises the preparation of a polyinosinic acid-polycytidylic acid solution and a preparation of a lyophilized powder injection thereof. According to the invention, proper amounts of polyinosinic acid and polycytidylic acid are respectively dissolved by using normal saline; the mixtures are mixed and stirred, such that the polyinosinic acid-polycytidylic acid solution is prepared; a lyophilization additive is added and well mixed; and filtering, sub-packaging, and lyophilization are carried out. The prepared injection is suitable for frost preservation under a temperature below 0 DEG C. Therefore, expiration date is postponed, oxidative degradation speed is reduced, toxic and side effect are reduced, and stability is improved.

The invention provides a polyinosinic acid-polycytidylic acid dominated adjuvant. The invention provides an oligonucleotide adjuvant composition and an immunoreaction initiated application method thereof. The invention also provides an immunogen composition containing the oligonucleotide adjuvant composition and an antigen, for example, the two components are in a vaccine. The adjuvant composition disclosed by the invention has specific physical properties such as molecular weight, concentration and pH, and the properties can meet a required effective and safe adjuvant capable of inducing and strengthening immunoreaction and changing the type of immunoreaction. The invention further relates to application methods of the adjuvant compositions, and particularly relates to a method for inducing the immunoreaction for antigen compositions.

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and/or Toll-like receptor7/8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The invention relates to a polyinosinic acid drop pill for pets and a method for preparing the same. The drop pill is prepared from polyinosinic acid, polycytidylic acid, a pH buffering system, an excipient and a substrate.

The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine). The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound.

The invention relates to a veterinary interferon inducer. The veterinary interferon inducer is prepared from the following components: a sodium chloride-phosphate buffer solution with the pH value of 7.2, a 10-80g/L calcium chloride aqueous solution, a 0.1-5g/L chitosan hydrochloride solution, polyinosinic acid and polycytidysic acid. The invention further provides a preparation method of the veterinary interferon inducer. The veterinary interferon inducer provided by the invention is few in side reaction, low in irritation and high in safety, and the preparation method can avoid precipitates generated by calcium chloride and other components.

The invention relates to a compound adjuvant composition and a vaccine composition containing the adjuvant. The compound adjuvant composition consists of an oil-in-water emulsion, polyinosinic acid-polycytidysic acid or derivatives thereof and DDA. Cellular immunity of antigen can be obviously improved.

The invention provides a subunit vaccine against Mycobacterium tuberculosis based on modification by arabinogalactan-polyinosinic acid polycytidylic acid and a preparation method thereof. The preparation method comprises the following steps: subjecting arabinogalactan (AG) and polyinosinic acid polycytidylic acid (poly(I:C)) to chemical coupling so as to prepare an AG-poly(I:C) conjugate which is used as an immunoadjuvant; subjecting antigen protein Ag85B expressed in a replicative period of Mycobacterium tuberculosis and antigen protein HspX expressed in an incubation period of Mycobacterium tuberculosis to recombinant fusion expression in Escherichia coli so as to obtain Ag85B-HspX fusion protein; and modifying the Ag85B-HspX fusion protein with the AG-poly(I:C) conjugate so as to obtain the subunit vaccine against Mycobacterium tuberculosis. The vaccine has a long cycle half-life period in a body and can stimulate the body to generate high-level humoral immune response and cellullar immune response.

The invention relates to the technical field of immunization, in particular to a polyinosinic: polycytidylic acid copolymer (Poly I: C). The polyinosinic: polycytidylic acid copolymer is a ligand of atype-3 Toll-like receptor in an animal body, can mediate a series of immune reactions of the body after TLR-3 is activated, and has a good promoting effect on specific immunity and non-specific immunity of the body. Compared with a control group, DC-CIK induced by the polyinosinic: polycytidylic acid copolymer has higher proliferation, high differentiation (especially CD3+CD4-CD8+, CTL) and hightumor killing activity. The autologous efficient DC-CIK induced by the polyinosinic: polycytidylic acid copolymer and other immune cells are applied to treatment of clinical tumor patients. The polyinosinic: polycytidylic acid copolymer aims to recover or improve the immune function of the tumor patients, and the immune system of the body is improved to kill and inhibit proliferation of tumor cells. The tumor cell load is reduced, tiny residual lesions are removed, or the proliferation mode of residual tumor/cancer cells is obviously inhibited, factors such as relapse and metastasis are eliminated, the cure possibility is increased, the survival time is prolonged, and the life quality is improved. Therefore, the purpose of treating tumors/cancers is achieved.

The invention relates to a polynucleotide microcapsule for treating animal disease and a preparation method thereof, belonging to the technical field of veterinary medicament preparation. Polyinosinic acid and polycytidylic acid are weighted and are added into preheated sodium chloride-phosphate buffer solution, and polynucleotide solution is prepared; the polynucleotide solution is added into ethyl cellulose to prepare soft wood and dry powder is prepared; the dry powder and magnesium stearate are added into ice-bath acetone to obtained a mixture, the mixture is stirred and slowly added into whiteruss containing 2%Span-80 surface active agent; and polynucleotide microcapsule is obtained by a method of in-liquid drying. The invention effectively prolongs the acting time of medicament within human body, decrease the applied time of the medicament and achieves the aims of long acting and sustained release. Experiments prove that the dead rate of the high dose group or the medium dose group of the polynucleotide microcapsule is obviously lower than that of an infectious control group. The cure rate is high, both are 80%, and the effective rate of the two groups are 100%. Experiments prove that the medicament of the invention is safe.

The invention provides a preparation method of refined poly zic and application, which are characterized in that polyinosinic acid and poly zic acid are purified via a chemical method, are merged into poly zic liquor after being refined respectively, and the poly zic liquor is ultra-filtered, concentrated and added with auxiliaries, so that the refined poly zic is prepared. The refined poly zic can effectively increase an anticancer effect.

The invention discloses a polyinosinic-polycytidylic acid injection and a method for lowering toxins in the polyinosinic-polycytidylic acid injection. Positive lipidosome is added in the polyinosinic-polycytidylic acid injection. The method comprises the steps: polyinosinic acid and polycytidylic acid are dissolved and mixed according to the set proportion, and a double-chain polyinosinic acid-polycytidylic acid polymer solution is formed; the positive lipidosome is added into the double-chain polyinosinic acid-polycytidylic acid polymer solution, thus a to-be-treated solution is obtained, andthe to-be-treated solution is magnetically stirred; and then the PH value of the to-be-treated solution is regulated, the to-be-treated solution subjected to PH value regulating is filtered, and thusthe polyinosinic-polycytidylic acid injection is obtained. According to the polyinosinic-polycytidylic acid injection and the method for lowering the toxins in the polyinosinic-polycytidylic acid injection, the toxins in the polyinosinic-polycytidylic acid injection are effectively lowered, safety and effectiveness of clinical medication are facilitated, and using and popularization are facilitated.

The invention belongs to a preparation method of poly i-c and belongs to the technical field of biomedicine. The preparation method includes: utilizing inosine diphosphate to prepare polyinosinic acid, and using cytidine diphosphate to prepare polycytidylic acid; utilizing the prepared polyinosinic acid to react with the polycytidylic acid to obtain a high-purity poly i-c product. Poly i-c is prepared through self-developed high-purity polyinosinic acid and polycytidylic acid, so that prepared poly i-c is high in purity, and treatment difficulty in the process of preparing is lowered.

The present invention relates to the technical field of liver immunology and experimental zoology, particularly to a method for establishing an acute viral hepatitis animal model, wherein D-galactosamine and polyinosinic acid:polycytidylic acid are injected in a peritoneal injection or intravenous injection manner, the D-galactosamine and the polyinosinic acid:polycytidylic acid produce the synergy effect, the ALT activity change is detected, and the acute viral hepatitis animal model is established. With the method of the present invention, the hepatitis symptoms are rapidly induced, and the viral infection simulation effect is good.

The invention discloses an application of polyinosinic acid combined with an anti-CD47 antibody in tumor treatment, which can promote the innate immune function of macrophages so as to improve the activation performance of the anti-CD47 antibody, promote the macrophages to kill tumor cells and improve the response rate of tumor patients to the anti-CD47 antibody. Meanwhile, when the polyinosinic acid is combined with the anti-CD47 antibody to treat tumors, adverse reactions such as anemia and the like caused in the treatment process can be remarkably reduced, and the life quality of a patientand the compliance in the treatment process are improved; more importantly, solid tumors including colon cancer can be treated by combining the Poly I: C immunologic adjuvant with the anti-CD47 antibody for immunotherapy, so that the restriction that the anti-CD47 antibody is difficult to realize an effective treatment effect on the solid tumors in the prior art is broken through; a new research direction is provided for immunotherapy and colon cancer treatment in the prior art, and development of the field of tumor treatment is promoted.

The invention discloses an EV71 vaccine containing an adjuvant combination. The EV71 vaccine is prepared from the following main components: EV71 virus-like particles (EV71-VLPs), an aluminum adjuvantand polyinosinic acid cytidylic acid (poly I: C). The immunogenicity of the EV71 protein vaccine provided by the invention is superior to that of monophosphate lipids A (MPLA), Al or a poly I: C adjuvant vaccine which is singly used currently; the EV71 vaccine not only can well induce humoral immune response with antigen specificity, but also can induce high-level cellular immune response; the vaccine can effectively prevent related diseases caused by EV71 virus infection.